JHU's Neurofibromatosis Therapeutic Acceleration Program celebrated the 10th anniversary of its Francis S. Collins Scholars ...

A new study led by Indiana University School of Medicine researchers revealed a potential strategy to address neurobehavioral ...

The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

The event, hosted by NF Network, included a 5K walk/run, a basket raffle and a time to share and spread awareness ...

The European Commission has approved EZMEKLY (mirdametinib) for treatment of symptomatic, inoperable plexiform neurofibromas ...

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted conditional marketing authorization ...

A new study led by Indiana University School of Medicine researchers revealed a potential strategy to address neurobehavioral ...

The European Commission granted conditional marketing authorization for Ezmekly (mirdametinib) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric and adult patients ...